Introduction
At present, there is no standard effective chemotherapy for the treatment of hepatocellular carcinoma. Agents such as doxorubicin and cisplatin have demonstrated poor efficacy in this indication [1, 2] . Interest in the use of thymidylate synthase inhibitors in this disease was prompted by the anti-tumour activity of CB3717 against hepatocellular carcinoma [3] . Raltitrexed (Tomudex'; ZD 1694) is a novel antifolate which is a direct and specific inhibitor of thymidylate synthase. In preclinical and clinical studies raltitrexed has shown activity against a variety of tumour types, including colorectal and breast cancer [4] . We report here the results of a phase II study of raltitrexed in patients with advanced hepatocellular cancer.
Patients and methods
Patients were recruited to this study between October 1992 and December 1993 and were aged > 18 years with histologically confirmed hepatocellular carcinoma. Patients also had at least 1 measurable lesion, a WHO performance status <2, a life expectancy >12 weeks and no other previous or current malignancy. Patients who had received prior cytotoxic therapy or irradiation of > 30% of the bone marrow, and those who were receiving concomitant anticancer therapy or folic acid were excluded. Corticosteroids were not allowed unless given as antiemetic or replacement therapy. Patients with intracerebral metastases, clinical ascites, encephalopathy or significant abnormality of biochemical markers of liver damage (level of bilirubin > 35 umol/1, albumin <35 g/1, or alanine aminotransferase [ALT] or aspartate aminotransferase [AST] >5 times the upper limit of the reference range) were also excluded. All patients gave informed consent to participate.
Patients were given raltitrexed 3.0 mg/m 2 as a 15-minute intravenous infusion, once every 21 days. Each patient was expected to receive up to six treatment cycles, with further cycles being allowed if there was any evidence of response. Each dose could be delayed by up * "Tomudex' is a trade mark, the property of Zeneca Limited.
to 21 days or reduced if toxicity were to become dose-limiting. All patients underwent a clinical examination, documentation of performance status, tumour measurement and laboratory tests at study entry. Assessments of objective tumour response and of a-fetoprotein concentrations were made every six weeks, irrespective of any delay in dose administration. Adverse events and haematology variables were assessed weekly during treatment and adverse events were graded according to World Health Organization (WHO) criteria. Clinical examination and blood biochemical analyses were performed at the time of each administration of raltitrexed. Clinical examinations, tumour response assessment and biochemical analyses were repeated three weeks after the last cycle.
Tumour responses were assigned according to the International Union Against Cancer (UICC) criteria. Documentation of a complete or partial objective response required two observations no less than four weeks apart.
Results
Thirty-three patients were enrolled into the study and their baseline pretreatment characteristics are shown in Table 1 . A total of 106 cycles (median two cycles/patient, range 0 to 12) were administered; three patients received more than 6 treatment cycles. Twenty-nine patients (88%) were classified as having received raltitrexed on time with no dosage modification (although one of these patients died without receiving raltitrexed and was not included in the efficacy and safety analyses). Dosage reductions were required in four patients, and in one of these the 21-day dosing interval was extended by an additional 15 days.
Twenty-six patients were evaluable, out of 32 initially included in the efficacy analysis (six patients had no objective assessment at week 6), and none had a complete or partial response. The best overall response was stable disease in 12 patients (46%) and disease progression in 14 patients (54%). It is of note that two patients (who received 8 and 11 cycles, respectively) had a 'good' minor response as shown by a reduction in tumour size of 40%-50%. In one of these patients, plasma a-feto- protein levels declined from 188 to 5 ug/1 and remained at that level for at least 21 weeks (until the end of followup). This patient and three other recipients of raltitrexed showed a reduction in plasma a-fetoprotein levels of >25% from baseline (range 60%-98%). Thus, raltitrexed demonstrated some evidence of activity in a total of five patients (19%). Thirty patients experienced adverse events and 16 patients had at least one serious adverse event. There were nine deaths during the study, three due to hepatocellular carcinoma alone and six due to hepatocellular carcinoma and adverse events that were, in general, apparently related to disease progression. Ten patients withdrew from the study due to adverse events.
The most common adverse events were asthenia (38% of patients), diarrhoea (38%) and nausea (34%). Severe asthenia was recorded for six patients (19%), grade 4 haematological toxicity (decreased white blood cell or platelet counts) for two patients (6%) and grade 3/4 diarrhoea for three patients (9%). These haematological and gastrointestinal toxicities were in general reversible and short-lived. Alopecia, severe vomiting and oral effects (stomatitis, moniliasis) were recorded infrequently (3%-9% of patients). Abnormalities in plasma markers of liver damage were common; 34% of patients experienced WHO grade 3 or 4 increase in transaminase activity, although such abnormalities were frequent at trial entry and may have been related to the underlying pathology. There were no treatment withdrawals associated with altered hepatic enzyme activity. There was no evidence of cumulative toxicity or of renal toxicity.
Discussion
Hepatocellular carcinoma is one of the most common malignancies accounting for up to 1 million deaths globally per annum [5] although incidence varies, with high incidence rates in Asia and Africa being associated with high endemic hepatitis B carrier rates and mycotoxin contamination of foodstuffs and soil [6] . Surgery is the first-line treatment option for this condition but few patients are suitable for resection and there is a high postoperative recurrence rate [7] . The poor prognosis of patients with nonresectable or recurrent hepatocellular carcinoma (few survive for one year) supports the rationale for the use of chemotherapy in the treatment of this disease [8] . Systemic chemotherapy, even employing agents recognised as having activity such as doxorubicin, elicits low response rates (around 10%) [9] and is associated with little or no survival benefit [2] . Locoregional therapy may offer a greater possibility of a response although it may be poorly tolerated and has no known effect on survival [1] .
Against this background, the present study showed that raltitrexed has some limited activity in patients with advanced hepatocellular carcinoma. There were no complete or partial responses but a 'good' minor response was recorded in two patients (8%), one of whom had a marked and sustained decrease in plasma ocfetoprotein levels. Three further patients had a decrease of > 25% in plasma levels of this tumour marker (range 60%-98%).
Raltitrexed was generally well tolerated with reversible and manageable toxicity. The toxicity profile was consistent with that predicted in phase I clinical trials [4] and there was no evidence of cumulative or renal toxicity. Abnormalities of plasma markers of liver damage were common but were often present at study entry and may have been related to the underlying disease.
Hepatocellular carcinoma is particularly aggressive and resistant to chemotherapy, and raltitrexed appeared to have some activity against this tumour in two patients in this study. However, there were no complete or partial responses to the drug, and further clinical investigations with raltitrexed alone at this dose level in patients with hepatocellular carcinoma may not be warranted.
